Medical device manufacturers use cytotoxicity testing to help prove that devices that come into contact with the human body are biocompatible. Testing results are critical for gaining market access, ...

This article and associated images are based on a poster originally authored by Denise Sullivan, Zhong Yu, Benjamin Streeter, Stacie Chvatal and Daniel Millard and presented at ELRIG Drug Discovery ...

Most cytotoxicity test “failures” trace back to controllable factors like device materials, sterilant or other chemical residues, or physicochemical characteristics of the extract - which means ...

Explore luminescence screening assays for drug discovery, including luciferase and ATP assays. Learn the principles, formats, advantages, and limitations.

An integrated suite of bioassays provides a coherent workflow to track antibody Fc effector activity across every stage of mAb drug development Potency assays that fail during tech transfer or ...

Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.

Understanding how drug discovery screening cascades are constructed and optimized is essential for minimizing false positives ...